U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
One Percent Rule Checklist For Safer Forex Trading Risk 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
